Trium Capital LLP Acquires New Holdings in HilleVax, Inc. (NASDAQ:HLVX)

Trium Capital LLP acquired a new position in shares of HilleVax, Inc. (NASDAQ:HLVX - Free Report) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 378,205 shares of the company's stock, valued at approximately $548,000. Trium Capital LLP owned 0.75% of HilleVax at the end of the most recent quarter.

Several other large investors have also modified their holdings of HLVX. Two Sigma Advisers LP lifted its holdings in shares of HilleVax by 76.8% during the 4th quarter. Two Sigma Advisers LP now owns 41,200 shares of the company's stock worth $85,000 after acquiring an additional 17,900 shares during the period. Two Sigma Investments LP lifted its stake in HilleVax by 76.3% in the fourth quarter. Two Sigma Investments LP now owns 55,535 shares of the company's stock valued at $115,000 after buying an additional 24,039 shares in the last quarter. Stonepine Capital Management LLC bought a new stake in shares of HilleVax in the fourth quarter worth $274,000. Millennium Management LLC raised its position in HilleVax by 59.6% during the fourth quarter. Millennium Management LLC now owns 411,820 shares of the company's stock worth $852,000 after acquiring an additional 153,815 shares in the last quarter. Finally, Lightspeed Management Company L.L.C. acquired a new stake in HilleVax during the fourth quarter worth approximately $4,847,000. 86.42% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Separately, HC Wainwright restated a "neutral" rating and issued a $2.00 price target on shares of HilleVax in a research note on Monday, March 31st.

HilleVax Stock Performance

Shares of HLVX stock traded down $0.01 on Friday, hitting $2.09. The company's stock had a trading volume of 104,764 shares, compared to its average volume of 325,137. The stock's 50 day moving average is $1.94 and its 200-day moving average is $1.85. HilleVax, Inc. has a fifty-two week low of $1.34 and a fifty-two week high of $2.15. The company has a market capitalization of $104.79 million, a PE ratio of -0.97 and a beta of 0.76.

HilleVax (NASDAQ:HLVX - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.37) by $0.25. On average, research analysts forecast that HilleVax, Inc. will post -2.64 earnings per share for the current year.

HilleVax Profile

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.